Is empagliflozin or dapagliflozin contraindicated in urinary catheterised patient
Reading File
Finding Sources
Finding Sources
Searching PubMed
SGLT2 inhibitor urinary catheter contraindication
Searching the Web
empagliflozin dapagliflozin contraindicated urinary catheterised patients SGLT2
Finding Sources
Reading Web Page
https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS…
Searching PubMed
SGLT2 inhibitor urinary tract infection catheter associated
Searching the Web
SGLT2 inhibitor indwelling urinary catheter safety guideline recommendation hospital
Finding Sources
Here is a thorough answer based on textbooks, clinical guidelines (ACC, Cleveland Clinic Journal, NSW Health), and current evidence:
SGLT2 Inhibitors (Empagliflozin / Dapagliflozin) in Urinary-Catheterised Patients
Short Answer
Urinary catheterisation is not a formal contraindication to SGLT2 inhibitors in the prescribing information for either empagliflozin or dapagliflozin. However, it is consistently flagged as a high-risk condition that warrants strong caution and is often an indication to withhold or temporarily discontinue these drugs - particularly during acute inpatient care.
Why Catheterised Patients Are at Elevated Risk
SGLT2 inhibitors work by blocking glucose reabsorption in the proximal tubule, resulting in continuous urinary glucose excretion (glucosuria). This glucose-rich urine creates a favourable environment for bacterial and fungal growth. Key points:
- Glucosuria promotes CAUTI. An indwelling urinary catheter already bypasses the normal host defences of the urinary tract (sphincter tone, voiding mechanics, mucosal flow). Superimposing SGLT2-induced glucosuria on a catheterised urinary tract substantially increases the risk of catheter-associated urinary tract infection (CAUTI), urosepsis, and pyelonephritis.
- Urinary stasis + glucosuria = high-risk combination. A 2017 case report described E. coli septicaemia in a 70-year-old man on dapagliflozin who had incomplete bladder emptying and urinary stasis - a scenario that directly parallels catheter-associated stasis. (University of Melbourne case report)
- Dapagliflozin vs empagliflozin: A meta-analysis of 52 RCTs (36,689 patients) found that only dapagliflozin 10 mg was independently associated with increased UTI risk vs. placebo; empagliflozin and canagliflozin did not increase UTI risk as a class, though genital infections rose with all agents. This suggests dapagliflozin carries a somewhat higher UTI-specific risk than empagliflozin, but both require caution in catheterised patients.
What Guidelines Actually Say
| Source | Position on Catheterised Patients |
|---|---|
| Cleveland Clinic Journal of Medicine (2025) | "It may be appropriate to temporarily withhold an SGLT2 inhibitor at least a few days before... while a short-term indwelling Foley catheter is being used." (CCJ) |
| PMC Real-Life Prescribing (2022) | Indwelling Foley catheter listed as a condition where "patients must be assessed on an individual basis, weighing the risks and benefits." Safety of SGLT2i in this group "has not been established." (PMC article) |
| NSW ACI Clinical Practice Guide (2023) | SGLT2i should not be routinely initiated or continued in acute inpatient settings; discontinue on admission to hospital as standard policy. |
| ACC Pocket Guide (SGLT2i in Heart Failure) | Cautions include urosepsis and pyelonephritis - "evaluate patients for signs and symptoms of urinary tract infections." |
| MDPI / Medicina (2025) | "Scenarios warranting extra caution or urology referral may include patients with indwelling catheters, ileal conduits, recurrent UTIs, or significant post-void residuals." Recommends multidisciplinary approach. |
Formal Contraindications vs. Cautions (What the Prescribing Info Says)
The official formal contraindications for both drugs are:
- Type 1 diabetes (due to DKA risk)
- Known hypersensitivity to the drug
- eGFR below threshold (dapagliflozin: <25 mL/min for HF/CKD indications, <45 mL/min for glycaemic; empagliflozin: <20-30 mL/min for glycaemic)
- Active bladder cancer (dapagliflozin only, per FDA labelling)
Urinary catheterisation is NOT in the formal contraindication list in the drug label. However, it appears in multiple clinical guidelines as a caution/risk condition warranting individual benefit-risk assessment.
Practical Recommendation
| Scenario | Action |
|---|---|
| Short-term catheter (e.g., post-op, acute illness) | Withhold SGLT2 inhibitor while catheter is in situ; restart after removal if no active UTI |
| Long-term/permanent catheter (e.g., neurogenic bladder) | Use with great caution - strong individual risk-benefit discussion required; generally avoided unless cardiorenal benefit clearly outweighs infection risk |
| Catheter in a hospitalised patient | Discontinue - consistent with the broader recommendation to stop SGLT2i in acute inpatient settings |
| Active UTI/CAUTI | Absolute clinical contraindication - hold drug until infection resolved |
Bottom Line
Neither empagliflozin nor dapagliflozin is formally contraindicated solely because of urinary catheterisation in official prescribing information. However, all major clinical guidelines and expert consensus strongly recommend withholding these drugs in catheterised patients - particularly acutely catheterised inpatients - because the combination of glucosuria and a catheter-disrupted urothelium creates a high risk of serious urinary/systemic infection. Dapagliflozin carries a slightly higher UTI-specific risk than empagliflozin based on meta-analysis data, but the caution applies to both agents.
This is a shared conversation. Sign in to Orris to start your own chat.